A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Tralokinumab (Primary) ; Corticosteroids
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ECZTRA 3
- Sponsors LEO Pharma
- 28 Oct 2019 Status changed from active, no longer recruiting to completed.
- 27 Feb 2019 Planned End Date changed from 30 Sep 2019 to 30 Oct 2019.
- 05 Dec 2018 Status changed from recruiting to active, no longer recruiting.